Eurofins Scientific SE (ERFSF)
USD 64.5
(-0.77%)
USD 64.5
(-0.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 135.7 Million EUR | -98.01% |
| 2022 | 3.7 Billion EUR | 12.23% |
| 2021 | 3.29 Billion EUR | 14.32% |
| 2020 | 2.88 Billion EUR | 5.37% |
| 2019 | 2.73 Billion EUR | 30.72% |
| 2018 | 2.09 Billion EUR | 29.33% |
| 2017 | 1.61 Billion EUR | 19.14% |
| 2016 | 1.35 Billion EUR | 28.26% |
| 2015 | 1.05 Billion EUR | 35.26% |
| 2014 | 783.56 Million EUR | 15.83% |
| 2013 | 676.46 Million EUR | 19.66% |
| 2012 | 565.3 Million EUR | 27.34% |
| 2011 | 443.93 Million EUR | -29.6% |
| 2010 | 630.54 Million EUR | 78.06% |
| 2009 | 354.12 Million EUR | 4.83% |
| 2008 | 337.82 Million EUR | 34.94% |
| 2007 | 250.35 Million EUR | 36.98% |
| 2006 | 182.77 Million EUR | 51.77% |
| 2005 | 120.42 Million EUR | 21.96% |
| 2004 | 98.74 Million EUR | 2.34% |
| 2003 | 96.48 Million EUR | 6.97% |
| 2002 | 90.2 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 57.6 Million EUR | 0.0% |
| 2023 Q2 | 362.8 Million EUR | 0.0% |
| 2023 FY | 73.6 Million EUR | -98.01% |
| 2023 Q4 | 465.3 Million EUR | 0.0% |
| 2022 Q4 | 272.99 Million EUR | 0.0% |
| 2022 FY | 3.7 Billion EUR | 12.23% |
| 2022 Q2 | 368.3 Million EUR | 0.0% |
| 2021 FY | 3.29 Billion EUR | 14.32% |
| 2021 Q2 | 374.4 Million EUR | 0.0% |
| 2021 Q4 | 383.3 Million EUR | 0.0% |
| 2020 Q4 | 321.79 Million EUR | 0.0% |
| 2020 FY | 2.88 Billion EUR | 5.37% |
| 2020 Q2 | 293.6 Million EUR | 0.0% |
| 2019 Q2 | 282.29 Million EUR | 0.0% |
| 2019 FY | 2.73 Billion EUR | 30.72% |
| 2019 Q4 | 280.5 Million EUR | 0.0% |
| 2018 Q2 | 177.9 Million EUR | 0.0% |
| 2018 FY | 2.09 Billion EUR | 29.33% |
| 2018 Q4 | 187.29 Million EUR | 0.0% |
| 2017 Q2 | 129.06 Million EUR | 0.0% |
| 2017 Q4 | 124.79 Million EUR | 0.0% |
| 2017 FY | 1.61 Billion EUR | 19.14% |
| 2016 Q2 | 89.91 Million EUR | 0.0% |
| 2016 Q4 | 77.42 Million EUR | 0.0% |
| 2016 FY | 1.35 Billion EUR | 28.26% |
| 2015 FY | 1.05 Billion EUR | 35.26% |
| 2015 Q2 | 75.94 Million EUR | 0.0% |
| 2015 Q4 | 100.45 Million EUR | 0.0% |
| 2014 FY | 783.56 Million EUR | 15.83% |
| 2014 Q4 | 66.7 Million EUR | 0.0% |
| 2014 Q2 | 62.62 Million EUR | 0.0% |
| 2013 Q4 | 43 Million EUR | 0.0% |
| 2013 Q2 | 51.32 Million EUR | 0.0% |
| 2013 FY | 676.46 Million EUR | 19.66% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 FY | 565.3 Million EUR | 27.34% |
| 2011 Q1 | 96.11 Million EUR | -82.13% |
| 2011 Q4 | 123.6 Million EUR | 10.26% |
| 2011 Q2 | 112.11 Million EUR | 16.65% |
| 2011 Q3 | 112.1 Million EUR | -0.01% |
| 2011 FY | 443.93 Million EUR | -29.6% |
| 2010 Q1 | 89.84 Million EUR | -66.1% |
| 2010 Q2 | 93.44 Million EUR | 4.0% |
| 2010 Q3 | 276.02 Million EUR | 195.39% |
| 2010 Q4 | 537.81 Million EUR | 94.85% |
| 2010 FY | 630.54 Million EUR | 78.06% |
| 2009 FY | 354.12 Million EUR | 4.83% |
| 2009 Q4 | 265.01 Million EUR | -0.23% |
| 2009 Q3 | 265.61 Million EUR | 199.4% |
| 2009 Q1 | 87.79 Million EUR | 0.0% |
| 2009 Q2 | 88.71 Million EUR | 1.06% |
| 2008 FY | 337.82 Million EUR | 34.94% |
| 2007 FY | 250.35 Million EUR | 36.98% |
| 2006 FY | 182.77 Million EUR | 51.77% |
| 2005 FY | 120.42 Million EUR | 21.96% |
| 2004 FY | 98.74 Million EUR | 2.34% |
| 2003 FY | 96.48 Million EUR | 6.97% |
| 2002 FY | 90.2 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -12836.13% |
| Arrayit Corporation | 6.19 Million USD | -2089.566% |
| Atlantic International Corp. | 5.57 Million USD | -2332.652% |
| Biocept, Inc. | 29.4 Million USD | -361.549% |
| Bioqual, Inc. | 7.44 Million USD | -1721.777% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -17474.488% |
| DermTech, Inc. | 104.01 Million USD | -30.462% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 18.499% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | -499.814% |
| iMD Companies, Inc. | 151.8 Thousand USD | -89288.64% |
| IDenta Corp. | 662.97 Thousand USD | -20368.343% |
| Interpace Biosciences, Inc. | 20.23 Million USD | -570.72% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -348913.657% |
| InVitro International | 661.32 Thousand USD | -20419.443% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | -1811.806% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -233414.593% |
| Medical Imaging Corp. | 1.91 Million USD | -6996.672% |
| NovelStem International Corp. | 3.53 Million USD | -3735.718% |
| Optigenex Inc. | 1.28 Million USD | -10436.786% |
| PharmChem, Inc. | 2.93 Million USD | -4529.457% |
| Proteome Sciences plc | 3.26 Million USD | -4052.387% |
| Response Genetics, Inc | 25.31 Million USD | -435.961% |
| Rennova Health, Inc. | 7.67 Million USD | -1667.437% |
| RushNet, Inc. | 1.78 Million USD | -7483.887% |
| ScreenPro Security Inc. | 3.23 Million USD | -4089.677% |
| Stella Diagnostics Inc. | 11.42 Million USD | -1087.543% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | -1748.014% |
| Todos Medical Ltd. | 14.05 Million USD | -865.287% |